Article Search

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

February 1, 2026

A B7 homolog 3–directed antibody-drug conjugate, demonstrated an overall response rate of 48.2%, with a median duration of response of 5.3 months, and a median progression-free survival of 4.9 months. The 9-month overall survival estimate was 59.1%. This represents another ADC with promising activity, although interstitial lung disease remains a concern, occurring in approximately 12% of patients.

Read More »

Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices

March 1, 2023

FCS medical oncologist and hematologist Lowell L. Hart, MD, FACP was first-author a study with FCS co-authors President and Managing Physician Lucio N. Gordan, MD, Director of Pharmacy Operations Kristen Boykin, Senior Vice President & Data Officer Trevor Heritage, PhD, and (Retired) Vice President of Pharmacy Services Ray Bailey BPharm, RPh, that evaluated ES-SCLC patients with chemotherapy-induced myelosuppression over a seven-year period, from January 2013 through December 2020. Within this cohort, 98% of the patients experienced at least one myelosuppressive episode following chemotherapy treatment, leading to the need for supportive care, creating additional costs in health care management and time lost in treatment for ES-SCLC.

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts